Ventricular Assist Device in Acute Myocardial Infarction

Original Title: Ventricular Assist Device in Acute Myocardial Infarction. Reference: Deepak Acharya et al. J Am Coll Cardiol. 2016;67(16):1871-1880.

 

Patients undergoing acute myocardial infarction (AMI) with acute cardiac failure or cardiogenic shock have a high mortality rate with the conventional treatment.

This study assessed the outcomes of patients with AMI receiving a durable ventricular assist device.

All patients in the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support) receiving a ventricular assist device in the context of AMI were included and compared with those receiving similar devices in other clinical contexts (not AMI).

In all, 502 patients with AMI received an assist device, 443 left ventricular assist devices; 33 biventricular assist devices; and 26 total artificial hearts.

Population mean age was 58.3 years and more than 70% were men.

In the group receiving the device in the context of AMI there was a higher proportion of patients had pre-operative intra-aortic balloon pumps (57.6% vs. 25.3%; p < 0.01), intubation (58% vs. 8.3%; p < 0.01), extracorporeal membrane oxygenation.

On month after ventricular assist device implantation, 91.8% of AMI patients were alive and continued with the support, 7.2% died on the device and 1% had a heart transplant.

After one year, 52% were alive and still on the support device, 25.7% had a heart transplant, 1.6% recovered and had the device removed, and 20.7% died on the device.

After adjusting for clinical differences, the AMI group requiring the device presented a short term mortality rate similar to that of the non AMI group (HR: 0.89; p = 0.30) but later on the first group saw a lower rate (HR: 0.55; p = 0.02).

Conclusion
Patients receiving a permanent ventricular assist device in the context of AMI in cardiogenic shock have a similar outcome to that of patients with similar devices despite being more critically sick prior implantation. Ventricular assist device implantation is an effective therapy for patients with post MI acute heart failure or cardiogenic shock when standard therapy fails.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....